Cardiovascular Pharmaceutical Market Trends, 2007 to 2010: Key market forecasts and growth opportunities

Table of Contents

Summary

• Introduction
• Key disease markets
• Key drug classes
• Key products
• Key companies
• Key trends and opportunities

Chapter 1. Introduction

• Global cardiovascular market
• Report overview
  • Methodology
  • Sources
  • Structure

Chapter 2. Key disease markets

• Key cardiovascular markets
  • Disease burden
  • Cardiovascular prevalence
  • Cardiovascular mortality
• Cardiovascular epidemiology
  • Hypertension
  • Dyslipidemia
  • Coronary heart disease

Chapter 3. Key drug classes

• Key drug classifications
• Anti-hypertensive drug class
• Leading anti-hypertensive drugs
• Anti-dyslipidemics drug class
  • Leading anti-dyslipidemic drugs
• Anti-thrombotics drug class
  • Leading anti-thrombotic drugs
• Selected others drug class
  • Leading cardiovascular selected others drugs

Chapter 4. Key products

• Leading products Top 10 leading cardiovascular drugs
  • Lipitor (atorvastatin)
  • Plavix (clopidogel)
  • Norvasc/ Amlodin (amlodopine)
  • Zocor (simvastatin)
  • Diovan/ Co-Diovan (valsartan)
  • Pravachol/ Mevalotin (pravastatin)
  • Cozaar/ Hyzaar (losartan)
  • Lovenox (enoxaparin)
  • Blopress/ Atacand (candesartan)
  • Aprovel/ Avapro/ Avalide (irbesartan)

Chapter 5. Key companies

• Major cardiovascular players Leading companies
  • Pfizer
  • Merck
  • Sanofi-Aventis
  • Bristol-Myers Squibb
  • Novartis
  • AstraZeneca
  • Daiichi Sankyo
  • Servier
  • GlaxoSmithKline
  • Boehringer Ingelheim

Chapter 6. Key trends and opportunities

• Key disease market forecasts
  • Global markets
  • Cardiovascular sites
• Key drug class forecasts
  • Anti-hypertensives
  • Anti-dyslipidemics
  • Anti-thrombotics
  • Selected others
• Key product forecasts
  • Lipitor (atorvastatin)
  • Plavix (clopidogel)
  • Norvasc/ Amlodin (amlodopine)
  • Zocor (simvastatin)
  • Diovan/ Co-Diovan (valsartan)
  • Pravachol/ Mevalotin (pravastatin)
  • Cozaar/ Hyzaar (losartan)
  • Lovenox (enoxaparin)
  • Blopress/ Atacand (candesartan)
  • Aprovel/ Avapro/ Avalide (irbesartan)
  • Forecast patent expiries
• Key company forecasts
  • Pfizer
  • Merck
  • Sanofi-Aventis
  • Bristol-Myers Squibb
  • Novartis
  • AstraZeneca
  • Daiichi Sankyo
  • Servier
  • GlaxoSmithKline
  • Boehringer Ingelheim

Appendix

• Proprietary data sources
  • Product Trends Database
  • R&D Trends Database
  • Company Trends Database
  • Market Trends Database
• Top 58 cardiovascular products
• Top 14 pharmaceutical companies by cardiovascular sales

List of Figures

• Figure 1: Global cardiovascular market, 2003-2005
• Figure 2: Report structure
• Figure 3: Disease burden for cardio in seven major pharmaceutical markets, 2005
• Figure 4: Prevalence for cardio in seven major pharmaceutical markets, 2005
• Figure 5: Cardio deaths in seven major pharmaceutical markets, 2005
• Figure 6: Hypertension epidemiology in seven major markets, 2005
• Figure 7: Dyslipidemia epidemiology in seven major markets, 2005
• Figure 8: Coronary heart disease epidemiology in seven major markets, 2005
• Figure 9: Global cardiovascular market by drug class, 2005
• Figure 10: Global cardiovascular market by drug class, 2003-2005
• Figure 11: Global cardiovascular market trends by drug class, 2004-2005
• Figure 12: Anti-hypertensives market, 2003-2005
• Figure 13: Leading anti-hypertensive drugs by approval date, 1974-2005
• Figure 14: Anti-dyslipidemics market, 2003-2005
• Figure 15: Leading anti-dyslipidemic drugs by approval date, 1991-2005
• Figure 16: Anti-thrombotic market, 2003-2005
• Figure 17: Leading anti-thrombotic drugs by approval date, 1954-2005
• Figure 18: Cardiovascular selected others market, 2003-2005
• Figure 19: Leading cardiovascular selected others drugs by approval date, 1971-2005
• Figure 20: Top 10 cardiovascular products by global sales, 2005
• Figure 21: Top 10 companies by global cardiovascular sales, 2005
• Figure 22: Top 10 companies by global cardiovascular market share, 2005
• Figure 23: Top 10 companies by global cardiovascular sales, 2004-2005
• Figure 24: Cardiovascular prevalence forecasts by geographic market, 2005-2010
• Figure 25: Cardiovascular prevalence forecasts by disease market, 2005-2010
• Figure 26: Global cardiovascular market forecast, 2003-2010
• Figure 27: Global cardiovascular market forecasts by drug class, 2003-2010
• Figure 28: Top 10 cardiovascular drugs by forecast sales, 2010
• Figure 29: Lipitor (atorvastatin) forecast sales, 2003-2010
• Figure 30: Plavix (clopidogel) forecast sales, 2003-2010
• Figure 31: Norvasc/ Amlodin (amlodopine) forecast sales, 2003-2010
• Figure 32: Zocor (simvastatin) forecast sales, 2003-2010
• Figure 33: Diovan/Co-Diovan (valsartan) forecast sales, 2003-2010
• Figure 34: Pravachol/ Mevalotin (pravastatin) forecast sales, 2003-2010
• Figure 35: Cozaar/ Hyzaar (losartan) forecast sales, 2003-2010
• Figure 36: Lovenox (enoxaparin) forecast sales, 2003-2010
• Figure 37: Blopress/ Atacand (candesartan) forecast sales, 2003-2010
• Figure 38: Aprovel/ Avapro/ Avalide (irbesartan) forecast sales, 2003-2010
• Figure 39: Forecast patent expiries by 2005 global sales, 2006-2015
• Figure 40: Top ten companies by cardiovascular sales trends, 2005-2010

List of Tables

• Table 1: Global cardiovascular market trends by drug class, 2003-2005
• Table 2: Leading anti-hypertensives drugs, 2005
• Table 3: Anti-hypertensives market trends, 2003-2005
• Table 4: Leading anti-dyslipidemic drugs, 2005
• Table 5: Anti-dyslipidemics market trends, 2003-2005
• Table 6: Leading anti-thrombotic drugs, 2005
• Table 7: Anti-thrombotic market trends, 2003-2005
• Table 8: Leading cardiovascular selected others drugs, 2005
• Table 9: Cardiovascular selected others market trends, 2003-2005
• Table 10: Top 20 cardiovascular products by global sales, 2003-2005
• Table 11: Lipitor (atorvastatin) profile, 2005
• Table 12: Plavix (clopidogel) profile, 2005
• Table 13: Norvasc/ Amlodin (amlodopine) profile, 2005
• Table 14: Zocor (simvastatin) profile, 2005
• Table 15: Diovan/ Co-Diovan (valsartan) profile, 2005
• Table 16: Pravachol/ Mevalotin (pravastatin) profile, 2005
• Table 17: Cozaar/ Hyzaar (losartan) profile, 2005
• Table 18: Lovenox (enoxaparin) profile, 2005
• Table 19: Blopress/ Atacand (candesartan) profile, 2005
• Table 20: Aprovel/ Avapro/ Avalide (irbesartan) profile, 2005
• Table 21: Top 10 companies by global cardiovascular sales, 2003-2005
• Table 22: Pfizer profile, 2005
• Table 23: Pfizer cardiovascular pipeline, 2005
• Table 24: Merck profile, 2005
• Table 25: Merck cardiovascular pipeline, 2005
• Table 26: Sanofi-Aventis profile, 2005
• Table 27: Sanofi-Aventis cardiovascular pipeline, 2005
• Table 28: Bristol-Myers Squibb profile, 2005
• Table 29: Bristol-Myers Squibb cardiovascular pipeline, 2005
• Table 30: Novartis profile, 2005
• Table 31: Novartis cardiovascular pipeline, 2005
• Table 32: AstraZeneca profile, 2005
• Table 33: AstraZeneca cardiovascular pipeline, 2005
• Table 34: Daiichi Sankyo profile, 2005
• Table 35: Daiichi Sankyo cardiovascular pipeline, 2005
• Table 36: Servier profile, 2005
• Table 37: Servier cardiovascular pipeline, 2005
• Table 38: GlaxoSmithKline profile, 2005
• Table 39: GlaxoSmithKline cardiovascular pipeline, 2005
• Table 40: Boehringer Ingelheim profile, 2005
• Table 41: Boehringer Ingelheim cardiovascular pipeline, 2005
• Table 42: Global cardiovascular market forecasts by drug class, 2003-2010
• Table 43: Top 10 cardiovascular drugs forecasts, 2003-2010
• Table 44: Top 10 companies by cardiovascular sales forecasts, 2005-2010
• Table 45: Top 58 cardiovascular products by global pharmaceutical sales, 2003-2005
• Table 46: Top 14 companies by global cardiovascular sales, 2003-2005